27,945 Shares in Bruker Corporation $BRKR Bought by Old West Investment Management LLC

Key Points

• Old West Investment Management LLC acquired 27,945 shares of Bruker Corporation during the 1st quarter, valued at approximately $1,166,000.
• Bruker recently declared a $0.05 quarterly dividend with an annualized dividend yield of 0.6%, payable on October 3rd.
• Analyst ratings have varied, with Barclays lowering its target price from $46 to $43, while Jefferies set a target of $60, indicating mixed sentiments about the stock's future performance.

Old West Investment Management LLC acquired a new position in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 27,945 shares of the medical research company's stock, valued at approximately $1,166,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new stake in Bruker during the 4th quarter valued at $661,000. Barclays PLC grew its holdings in Bruker by 58.2% during the 4th quarter. Barclays PLC now owns 88,086 shares of the medical research company's stock valued at $5,164,000 after buying an additional 32,401 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Bruker by 22.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,687,364 shares of the medical research company's stock valued at $98,914,000 after buying an additional 313,171 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Bruker by 58.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,257 shares of the medical research company's stock valued at $425,000 after buying an additional 2,687 shares during the last quarter. Finally, OneDigital Investment Advisors LLC grew its holdings in Bruker by 9.9% during the 4th quarter. OneDigital Investment Advisors LLC now owns 4,002 shares of the medical research company's stock valued at $235,000 after buying an additional 362 shares during the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Stock Up 5.1%

Shares of BRKR opened at $35.54 on Monday. The firm has a market cap of $5.39 billion, a PE ratio of 68.35, a price-to-earnings-growth ratio of 2.94 and a beta of 1.16. The company's fifty day moving average is $38.48 and its two-hundred day moving average is $40.83. Bruker Corporation has a fifty-two week low of $30.00 and a fifty-two week high of $72.94. The company has a quick ratio of 0.70, a current ratio of 1.61 and a debt-to-equity ratio of 1.31.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a return on equity of 17.89% and a net margin of 2.31%.The business had revenue of $797.40 million during the quarter, compared to analyst estimates of $811.17 million. During the same period in the previous year, the company earned $0.52 EPS. Bruker's revenue was down .4% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. Analysts forecast that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd will be given a dividend of $0.05 per share. The ex-dividend date is Tuesday, September 23rd. This represents a $0.20 annualized dividend and a dividend yield of 0.6%. Bruker's dividend payout ratio (DPR) is 38.46%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on BRKR shares. Barclays lowered their target price on Bruker from $46.00 to $43.00 and set an "overweight" rating on the stock in a report on Monday, August 4th. Jefferies Financial Group set a $60.00 price target on Bruker and gave the company a "buy" rating in a report on Monday, August 4th. The Goldman Sachs Group cut their price target on Bruker from $50.00 to $45.00 and set a "neutral" rating for the company in a report on Thursday, May 8th. Stifel Nicolaus set a $40.00 price target on Bruker and gave the company a "hold" rating in a report on Tuesday, August 5th. Finally, UBS Group cut their price target on Bruker from $57.00 to $45.00 and set a "neutral" rating for the company in a report on Thursday, May 8th. Five investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $51.30.

Insider Activity

In other news, CEO Frank H. Laukien purchased 2,608 shares of the stock in a transaction dated Friday, June 6th. The shares were bought at an average cost of $38.36 per share, for a total transaction of $100,042.88. Following the transaction, the chief executive officer owned 38,462,171 shares in the company, valued at $1,475,408,879.56. This trade represents a 0.01% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 27.30% of the company's stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.